GSK2256294
Sponsors
GlaxoSmithKline, Oregon Health and Science University, Vanderbilt University Medical Center
Conditions
Delayed Cerebral IschemiaDiabetes MellitusEndocrine System DiseasesEndothelial DysfunctionGlucose Metabolism DisordersObesityPreDiabetesPulmonary Disease, Chronic Obstructive
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers
CompletedNCT01762774
Start: 2013-01-16End: 2014-05-01Updated: 2017-05-09
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects
CompletedNCT02006537
Start: 2014-01-31End: 2014-05-27Updated: 2017-05-09
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
CompletedNCT02262689
Start: 2015-01-08End: 2015-04-24Updated: 2017-05-09
Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
CompletedNCT03318783
Start: 2018-05-02End: 2020-01-09Updated: 2021-01-22